8 results about "Encephalitis" patented technology

The present invention provides compositions for the prevention and treatment of genital herpes, comprising nucleoside modified mRNAs that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, and methods of use thereof.

Described herein are single-domain antibodies that might serve as alternatives to conventional monoclonal antibodies for either the detection or treatment of Venezuelan equine encephalitis virus (VEEV).

The application relates to application of CTRP4 in condition assessment and treatment of herpes simplex encephalitis, belongs to the technical field of biological medicine, and solves one of the problems that the condition assessment of HSE in the prior art is highly subjective, an imaging examination cannot reflect intracranial core lesions in real time and dynamically, is not related to a core biological mechanism of a disease, brain tissue samples are difficult to obtain, direct and effective indexes of intracranial disease states are scarce, and routine laboratory examinations are not specific for central nervous system pathologies and recovery of nerve functions. The application comprises application of CTRP4 in preparation of a herpes simplex encephalitis diagnostic reagent, and the diagnostic reagent is used for detecting the expression level of CTRP4 in a biological sample of a subject. The application of CTRP4 in preparation of the herpes simplex encephalitis diagnostic reagent can provide a highly specific, non-invasive and dynamic herpes simplex encephalitis condition assessment scheme, and solves the limitation problem of subjective diagnosis by doctors in traditional assessment.

This invention provides a novel target PDE4B for the prevention and treatment of Cryptococcus neoformans brain infection. Specifically, it relates to the application of drugs targeting phosphodiesterase PDE4B in the preparation of drugs for the prevention and / or treatment of Cryptococcus neoformans meningoencephalitis. The drug targeting PDE4B is the PDE4B agonist MR-L2 (CAS: 2374703-19-0). The PDE4B agonist MR-L2 described in this invention can significantly reduce Cryptococcus neoformans brain infection, providing an effective prevention and treatment method for Cryptococcus neoformans meningoencephalitis.

Provided is an alphavirus nonstructural protein 3 (nsP3) that is modified by at least a mutation at an amino acid position corresponding to amino acid position 167 of wild-type Venezuelan equine encephalitis virus (VEEV) nsP3 of SEQ ID NO: 1.

The application relates to the technical field of biotechnology, and particularly discloses a recombinant NMDA receptor protein and application thereof, wherein the recombinant NMDA receptor protein comprises an amino acid sequence shown in SEQ ID No. 1. The application further provides a cell stably overexpressing the recombinant NMDA receptor protein and applying the cell to preparation of an anti-NMDA receptor antibody encephalitis detection product. The recombinant NMDA receptor protein is constructed by combining a core sequence of HSP70 protein with a complete sequence of the NMDA receptor protein, so that the expression amount of the recombinant NMDA receptor protein is higher, and the binding capacity with the anti-NMDA receptor antibody is stronger. The cell stably overexpressing the recombinant NMDA receptor has a higher binding efficiency with the anti-NMDA receptor antibody, the sensitivity of a detection reaction is further improved, and the detection result is more accurate.

This invention discloses a fusion protein for detecting autoantibodies against NMDAR-type encephalitis and its application, belonging to the field of medical detection technology. The fusion protein includes an NR1 protein and at least one selected from NR2B-eGFP or NR2B-mRFP fusion proteins, wherein the NR1 protein is an NR1 subunit; the NR2B-eGFP fusion protein is formed by replacing the S2 amino acid sequence of the NR2B subunit with eGFP; the NR2B-mRFP fusion protein is formed by replacing the S2 amino acid sequence of the NR2B subunit with mRFP. Experiments have shown that the fusion protein of this invention can effectively disrupt the binding ability of glutamate to the NMDAR receptor, thereby eliminating glutamate-induced cytotoxicity, and can retain the overall spatial conformation of the NMDAR receptor and key autoantibody recognition epitopes, significantly improving the sensitivity and specificity of NMDAR autoantibody detection based on live cells.

The application discloses a human respiratory tract coronavirus cross-reactive T cell epitope map and a delivery method thereof. The application draws a cross-reactive T cell epitope map among 7 HCoVs, and further screens an epitope fragment with high conservation from the identified cross-epitopes, so as to provide a core theoretical basis and experimental basis for development of a broad-spectrum HCoVs immune target; then, a Venezuelan equine encephalitis virus replicon vaccine precision delivery system capable of expressing a single conservative epitope is constructed for the screened conservative epitope fragment, so that the targeted delivery of the single conservative cross-reactive T cell epitope is realized, and a key technical bottleneck of low cross-epitope delivery efficiency in the existing HCoVs vaccine is solved.